For research use only. Not for therapeutic Use.
Gresonitamab（Cat No.:I042241）is a monoclonal antibody being studied for its potential in cancer immunotherapy. It targets the receptor CD47, a protein often overexpressed on cancer cells that acts as a “don’t eat me” signal, inhibiting macrophages and other immune cells from attacking the tumor. By blocking CD47, Gresonitamab enhances the immune system’s ability to recognize and destroy cancer cells. Research is ongoing to evaluate its safety and efficacy in treating a variety of cancers, including hematologic and solid tumors. Gresonitamab is being explored as part of innovative cancer therapies that promote immune system activation.
| Catalog Number | I042241 |
| CAS Number | 2413817-97-5 |
| Purity | ≥95% |
